Biotherapeutics firm 4d Pharma PLC (LON:DDDD) has bought a Spanish contract research group, which provides the group with its own production facilities.
Biomar, based in north-west Spain, has been an outsourced development partner of the firm since 2014 but now it has bought it for €3 million, payable on completion.
Alex Stevenson, 4D's chief scientific officer, said: "Over the past 12 months, we have witnessed first-hand the issues of relying on third party providers for the production of our product for clinical and development programmes.
"As our pace of development continues, with more of our programmes moving towards the clinic, 4D needs continued access to its own facilities to meet the challenges of our ambitious clinical development programmes, but also in looking forward to our initial production requirements."
Biomar initially focused on research into marine microorganisms, but in 2001 began to expand its technologies into microbial fermentation, providing contract services in this field and expanding its production capabilities up to 3,000 litres in 2010.
Shares eased 1.54% to 960p.